Universal 'test and trace' for HIV cost-effective in high prevalence regions

HIV
Microscopic image of an HIV-infected T cell. Credit: NIAID

Rolling out home-based testing and universal treatment for HIV is cost-effective and can cut the incidence of cases in high-prevalence communities.

These are the findings of a major HIV-prevention study involving more than one million people in Zambia and South Africa.

Using modeling of HIV incidence and the cost of the interventions, researchers found that widespread home-testing for HIV and the onward referral and treatment of positive cases, can be delivered at an annual cost of less than $8 per person.

According to the team, while this universal test and trace (UTT) approach carries a significant cost when scaled up to the , in regions with a high prevalence of HIV/AIDS it is a cost-effective strategy to control the HIV epidemic.

The findings, led by researchers from Imperial College London and the London School of Economics and Political Science (LSE), with collaborators from Oxford University, the London School of Hygiene and Tropical Medicine, Desmond Tutu TB Centre at Stellenbosch University (South Africa) and Zambart (Zambia) are published today in Lancet Global Health.

Dr. Katharina Hauck, from the School of Public Health at Imperial College London, said: "HIV/AIDS continues to cause a devastating burden globally. Unfortunately, having highly effective medical treatments does not mean they reach those who need them most. Our study demonstrates that large-scale testing and treatment strategies are expensive, but they are worthwhile to implement in regions with high prevalence of the disease because they make a great difference."

The PopART trial, which ran from 2013 to 2018, was the largest community-randomized trial of the universal test and treat strategy, covering a total population of one million people across high HIV-burden urban settings in Zambia and Western Cape, South Africa.

In the latest analysis, researchers combined modeling of HIV transmission to project and averted infections over a 17 year period, from the start of the trial until 2030.

The analysis revealed it is possible for a package of HIV prevention methods to be delivered through community health workers at scale for a low per person annually—equating to $6.53 in Zambia and $7.93 in South Africa (US Dollars).

This package of interventions includes door-to-door home-based counseling and testing; linkage-to-care; promotion of antiretroviral therapy (ART) adherence; and voluntary medical male circumcision.

The economics team integrated an individual-based model of HIV transmission with a cost-effectiveness analysis to project costs and averted infections until 2030. Using Disability Adjusted Life Years (DALY) – a measure linking the burden of disease in populations with the degree of illness, disability, and long-term survival—the team found the incremental cost-effectiveness ratio was $2,111 and $3,248 per HIV-infection averted and $593 and $645 per DALY averted in Zambia and South Africa, respectively. This means, for example, that it costs $593 to 'buy' one healthy life year with these interventions in Zambia.

Their models suggested a sustained reduction in HIV incidence with UTT delivered to 2030. Overall, their analysis showed that when comparing the benefits and costs, the intervention would be considered cost-effective implementing in settings with high HIV prevalence, compared to offering clinic-based HIV services only.

Critical findings for policy makers

The researchers believe the findings from this study are critical for policy makers to determine whether the package of HIV prevention interventions delivered under PopART is cost-effective and affordable for their setting.

Professor Sarah Fidler, Professor of HIV and Communicable Diseases at Imperial and co-principal investigator of the PopART study, said: "The PopART study is the largest, randomized trial of universal test and treat program for HIV/AIDS which showed this approach reduces the number of new HIV infections. It continues to provide important insights into community-based strategies for the management and prevention of HIV-AIDS in high incidence communities."

Professor Richard Hayes, Professor of Epidemiology and International Health at LSHTM, and principal investigator of the PopART trial said: "The trial results, published in the New England Journal of Medicine in July 2019, showed that the PopART combination prevention package reduced HIV incidence in the general population by around 20%.

"This is a substantial effect that would build up over time if the intervention were sustained. These new data, quantifying the cost of the intervention and its cost-effectiveness, are very important and will be of great value to health policy makers considering how to substantially reduce HIV incidence during the coming decade to achieve the UNAIDS targets for elimination."


Explore further

HPTN 071 modelling and cost analyses show benefits of community HIV testing and treatment

More information: Ranjeeta Thomas et al. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial, The Lancet Global Health (2021). DOI: 10.1016/S2214-109X(21)00034-6

Richard J. Hayes et al. Effect of Universal Testing and Treatment on HIV Incidence—HPTN 071 (PopART), New England Journal of Medicine (2019). DOI: 10.1056/NEJMoa1814556

Citation: Universal 'test and trace' for HIV cost-effective in high prevalence regions (2021, March 15) retrieved 14 April 2021 from https://medicalxpress.com/news/2021-03-universal-hiv-cost-effective-high-prevalence.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
14 shares

Feedback to editors

User comments